Sanofi
Sanofi, a global healthcare leader headquartered in France, is renowned for its commitment to improving health and well-being. Founded in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Operating within the pharmaceutical and biotechnology industry, Sanofi focuses on several main business areas, including prescription medicines, vaccines, and consumer healthcare products. Its core offerings, such as innovative treatments for diabetes, rare diseases, and vaccines, are distinguished by their scientific rigor and patient-centric approach. With a robust market position, Sanofi has achieved notable milestones, including advancements in immunology and oncology, solidifying its reputation as a trusted name in global health solutions.
DitchCarbon Score
How does Sanofi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sanofi's reported carbon emissions
In 2024, Sanofi reported total greenhouse gas emissions of approximately 4,196,976,000 kg CO2e, with Scope 1 emissions at about 298,485,000 kg CO2e, Scope 2 emissions (market-based) at approximately 75,864,000 kg CO2e, and Scope 3 emissions reaching about 3,822,627,000 kg CO2e. The company has set ambitious targets to reduce its carbon footprint, aiming for a 55% reduction in absolute Scope 1 and 2 emissions by 2030, compared to a 2019 baseline. Additionally, Sanofi is committed to achieving net-zero emissions across its entire value chain by 2045. For Scope 3 emissions, which include indirect emissions from purchased goods and services, business travel, and employee commuting, Sanofi aims for a 30% reduction by 2030. The company also plans to increase its sourcing of renewable electricity from 11% in 2019 to 100% by 2030. Long-term, Sanofi targets a 90% reduction in absolute emissions across all scopes by 2045, reinforcing its commitment to align with the 1.5°C climate goal. Sanofi's headquarters is located in France, and its climate initiatives reflect a proactive approach to sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sanofi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
